EMA Publishes Brexit Plan
The agency has published a continuity plan for its move from the United Kingdom.
On October 16, 2017, the European Medicines Agency (EMA) published a Brexit Preparedness Business Continuity Plan detailing how the agency will continue its operations while it prepares for relocation to a new host city because of the United Kingdom’s departure from the European Union. The plan, which was endorsed by the Management Board in June, was developed to deal with the workload implications and uncertainties related to Brexit.
The plan describes the methodology the agency has used to categorize and prioritize activities and the reallocation of resources, if needed. Tasks and activities have been classified into three categories based on priority. Activities in these categories are described as well as details regarding how and when implementation of changes will occur. The agency plans on continuously reviewing and adapting the plan as necessary.
Source: EMA
Texas' MD Anderson Cancer Center Creates New Cell Therapy Institute
November 11th 2024With the launch of the Institute for Cell Therapy Discovery and Innovation, the MD Anderson Cancer Center will bring together expertise in developing cell therapies for cancer, autoimmune diseases, and infections.
